陕西鼓励研发仿制药为患者减负

2018-08-09 薛寒 周垚 健康报网

陕西省政府日前出台《陕西省改革完善仿制药供应保障及使用政策工作方案》提出,通过改革完善仿制药供应保障及使用政策,提高药品供应保障能力,降低医疗成本和群众药品费用负担。

陕西省政府日前出台《陕西省改革完善仿制药供应保障及使用政策工作方案》提出,通过改革完善仿制药供应保障及使用政策,提高药品供应保障能力,降低医疗成本和群众药品费用负担。

《方案》提出,鼓励企业仿制临床必需、疗效确切、供应短缺的药品,仿制重大传染病防治和罕见病治疗所需药品,处置突发公共卫生事件所需药品,儿童使用药品以及专利到期前一年尚没有提出注册申请的药品。促进创新药研发和仿制药技术攻关,对研发出防治重特大传染病疫情或重特大疾病新药,并在该省实现产业化生产的企业或个人,以项目形式进行奖补,奖补金额不少于200万元。对在该省生产国家鼓励仿制药品目录内药品的企业,可不受销售增幅限制,享受当年同等规模企业超销售奖励政策。同时,加强对药用原辅料、包装材料及药物研发、生产、流通等过程的监督检查,加强不良反应监测和质量抽查,严肃查处数据造假、偷工减料、掺杂使假等违法违规行为,强化责任追究,检查和处罚结果及时向社会公开。

《方案》明确,完善仿制药采购政策,对通过质量和疗效一致性评价的仿制药品种和符合相关规定视同通过一致性评价的药品,在集中采购时执行与原研药同等政策。同时,促进仿制药优先配备使用,将通过质量和疗效一致性评价的仿制药纳入与原研药可相互替代药品目录,并及时通过药品采购平台向社会公布相关信息,便于医疗机构和患者选择使用。

《方案》要求,发挥基本医疗保险激励作用。按照国家统一部署和要求,加快制定医保药品支付标准,对与原研药质量和疗效一致的仿制药,按原研药相同标准支付。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994906, encodeId=5a8a1994906e4, content=<a href='/topic/show?id=27b91033e122' target=_blank style='color:#2F92EE;'>#鼓励研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103371, encryptionId=27b91033e122, topicName=鼓励研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Mar 30 07:24:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648989, encodeId=be7c1648989c6, content=<a href='/topic/show?id=5f36312836f' target=_blank style='color:#2F92EE;'>#减负#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31283, encryptionId=5f36312836f, topicName=减负)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6323702474, createdName=cnxcy, createdTime=Sun Oct 28 06:24:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261435, encodeId=bea21261435df, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300180, encodeId=528613001807b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337562, encodeId=75ed33e562be, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Aug 09 21:25:49 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994906, encodeId=5a8a1994906e4, content=<a href='/topic/show?id=27b91033e122' target=_blank style='color:#2F92EE;'>#鼓励研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103371, encryptionId=27b91033e122, topicName=鼓励研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Mar 30 07:24:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648989, encodeId=be7c1648989c6, content=<a href='/topic/show?id=5f36312836f' target=_blank style='color:#2F92EE;'>#减负#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31283, encryptionId=5f36312836f, topicName=减负)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6323702474, createdName=cnxcy, createdTime=Sun Oct 28 06:24:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261435, encodeId=bea21261435df, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300180, encodeId=528613001807b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337562, encodeId=75ed33e562be, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Aug 09 21:25:49 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-10-28 cnxcy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994906, encodeId=5a8a1994906e4, content=<a href='/topic/show?id=27b91033e122' target=_blank style='color:#2F92EE;'>#鼓励研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103371, encryptionId=27b91033e122, topicName=鼓励研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Mar 30 07:24:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648989, encodeId=be7c1648989c6, content=<a href='/topic/show?id=5f36312836f' target=_blank style='color:#2F92EE;'>#减负#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31283, encryptionId=5f36312836f, topicName=减负)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6323702474, createdName=cnxcy, createdTime=Sun Oct 28 06:24:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261435, encodeId=bea21261435df, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300180, encodeId=528613001807b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337562, encodeId=75ed33e562be, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Aug 09 21:25:49 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994906, encodeId=5a8a1994906e4, content=<a href='/topic/show?id=27b91033e122' target=_blank style='color:#2F92EE;'>#鼓励研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103371, encryptionId=27b91033e122, topicName=鼓励研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Mar 30 07:24:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648989, encodeId=be7c1648989c6, content=<a href='/topic/show?id=5f36312836f' target=_blank style='color:#2F92EE;'>#减负#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31283, encryptionId=5f36312836f, topicName=减负)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6323702474, createdName=cnxcy, createdTime=Sun Oct 28 06:24:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261435, encodeId=bea21261435df, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300180, encodeId=528613001807b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337562, encodeId=75ed33e562be, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Aug 09 21:25:49 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-11 lqvr
  5. [GetPortalCommentsPageByObjectIdResponse(id=1994906, encodeId=5a8a1994906e4, content=<a href='/topic/show?id=27b91033e122' target=_blank style='color:#2F92EE;'>#鼓励研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103371, encryptionId=27b91033e122, topicName=鼓励研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ed3112, createdName=echonoir, createdTime=Sat Mar 30 07:24:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648989, encodeId=be7c1648989c6, content=<a href='/topic/show?id=5f36312836f' target=_blank style='color:#2F92EE;'>#减负#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31283, encryptionId=5f36312836f, topicName=减负)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d6323702474, createdName=cnxcy, createdTime=Sun Oct 28 06:24:00 CST 2018, time=2018-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1261435, encodeId=bea21261435df, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25592, encryptionId=b56025592eb, topicName=仿制药)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300180, encodeId=528613001807b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Aug 11 10:24:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337562, encodeId=75ed33e562be, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Thu Aug 09 21:25:49 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 医者仁心5538

    好消息

    0

相关资讯

让老百姓用得起好药,上海全力推进仿制药质量疗效一致性评价

2015年起,国家通过推进药品审评审批制度改革来加快新药、好药的上市,在这方面,上海已经取得哪些进展?7月24日,上海市食药监局副局长陈尧水在上海市政府新闻发布会上表示,中国经过改革开放四十年,基本解决了缺医少药问题,现在的突出问题是要让老百姓用得上新药、好药。为此,上海市食药监局主要开展了三方面工作。一是在全国率先开展药品上市许可人制度试点,来促进创新研发生产,加快新药上市。经过两年多努力,上海

药价太高怎么办?美国:进口国外仿制药增加市场竞争

围绕电影《我不是药神》的讨论已经逐渐平息,但如何降低药价却是不变的话题,在美国也不例外。为降低药品价格,美国食品药品监督管理局(FDA)近日发表声明称,在美国卫生和公共服务部(HHS)的指导下,FDA正在筹建一个工作小组,专门进行美国进口仿制药的具体审计工作,研究制定进口仿制药物政策。引入仿制药,通过市场竞争降低药价药品价格过高始终是美国总统特朗普的一个“心病”,自上任以来,多次演讲中提出要

仿制药一致性评价时间节点将至 289种基本药物将何去何从?

截止目前,在已公布通过一致性评价的57个受理号中,基本药物口服制剂未过半数,为什么基本药物一致性评价进度缓慢?企业遇到了哪些阻力?距离年终仅剩4个月,这些基本药物将何去何从?

鼓励仿制替代原研?三位院士向医药创新机制“开炮”

近期,多起直击民生问题的医药相关热点事件与国际形势变化,引起社会各界广泛关注。随着国家提出的2020年转变为创新型国家,进口抗癌药实施零关税,加快境外上市新药审批,通过一致性评价的产品逐步替换原研等一系列政策,再次激发了人们对创新药和仿制药的讨论。

仿制药无法替换原研 谁说的?

目前,中国是一个仿制药大国,中国本土企业生产的药品中约有97%为仿制药。而在临床实践中,不可避免的,国产仿制药和原研药在疗效等方面存在较大差异。因此,就出现了一致性评价,意在提高仿制药审评标准,减少低质量供给。一致性评价就等效原研,有争议由于专利药的制剂工艺都是保密的,仿制药只能根据处方组成和给药途径来自行进行工艺研究,这会导致仿制药和原研药疗效和安全性的差异。比如,以某个治疗勃起功能障碍的西

国家药监局:这些药加快上市

在仿制药方面,重点提到激励药品仿制,加快推进仿制药品质量和疗效一致性评价工作,逐步提高已上市药品质量,并制定发布在临床上与原研药品相互替代的药品目录,即中国上市药品目录集。要求仿制药与原研药一致,实现临床可替代,从而提高仿制药质量,降低医疗费用。